Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Cohorts, trials, and evidence: expanding our confidence in guidelines for antiretroviral resistance testing.

Volberding P.

Ann Intern Med. 2009 Jul 21;151(2):135-6. No abstract available.

PMID:
19620166
2.

HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.

Simon VA; Aaron Diamond AIDS Research Center, New York, USA.

IAPAC Mon. 2001 Aug;7(8):235-7. No abstract available.

PMID:
11708276
3.

HIV resistance testing in clinical practice: a Qaly-fied success.

Saag MS.

Ann Intern Med. 2001 Mar 20;134(6):475-7. No abstract available.

PMID:
11255523
4.

Limitations and uncertainties of resistance testing: a review of "negative" trials. IAPAC sessions 2001, July 18-19, 2001 - Chicago.

Sherer R; Rush Medical College, Chicago, Illinois, USA.

IAPAC Mon. 2001 Aug;7(8):237-41. No abstract available.

PMID:
11708277
5.

The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study.

Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT; HOPS (HIV Outpatient Study) Investigators.

Ann Intern Med. 2009 Jul 21;151(2):73-84.

PMID:
19620160
6.

Difficulties encountered with antiretroviral treatment and genotypic testing of HIV-1 drug resistance in the developing countries: the Tunisian experience (North Africa).

Tebourski F, Jlizi A, Elgaaied A, Slim A, Garbouj M.

J Clin Virol. 2004 Jan;29(1):69-70. No abstract available.

PMID:
14675873
7.

The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy.

Palmisano L, Galluzzo CM, Giuliano M.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):233-4. doi: 10.1097/QAI.0b013e3181a5b247. No abstract available.

PMID:
19465827
8.

New data brings resistance testing closer to routine clinical use.

Murphy MJ.

Fac Notes (New Orleans La). 1999 May-Jun;11(3):6. No abstract available.

PMID:
11810872
9.

HIV viral resistance to antiretroviral drugs: foreword.

Ippolito G.

Scand J Infect Dis Suppl. 2003;106:4. No abstract available.

PMID:
15000571
10.

Editorial comment: resistance testing--an integral part of HIV management.

Katzenstein DA.

AIDS Read. 2003 Jan;13(1):36. No abstract available.

PMID:
12569893
11.

[HAART-update for the general practitioner].

Vogel M, Rockstroh JK.

MMW Fortschr Med. 2011 May 5;153(18):32-4. Review. German. No abstract available.

PMID:
21604592
12.

[Highly active antiretroviral therapy. Building on experience in developing new strategies].

Paukstadt W.

MMW Fortschr Med. 2011 May 5;153(18):39. German. No abstract available.

PMID:
21604595
13.

[Resistance screening].

Sierra S, Lengauer T, Kaiser R.

MMW Fortschr Med. 2009 Apr 30;151(18):72, 74-5. German. No abstract available.

PMID:
19769083
14.

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.

Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group.

J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19.

15.

The value of resistance testing.

Albrecht H.

AIDS Clin Care. 2002 May;14(5):46. No abstract available.

PMID:
12004878
16.

[Highly active antiretroviral therapy].

Jablonowski H.

MMW Fortschr Med. 2009 Apr 30;151(18):58-61. German. No abstract available.

PMID:
19769079
17.

[How HIV treatment can be simplified. "Once daily" as starter therapy is effective].

Wepner U.

MMW Fortschr Med. 2009 Apr 30;151(18):80-1. German. No abstract available.

PMID:
19769085
18.

HIV-1 group O sensitivity to antiretroviral drugs.

Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-V├ęzinet F.

AIDS. 1995 Aug;9(8):977-8. No abstract available.

PMID:
7576340
19.

Treatment of HIV-1 infection: is it time to hit early again?

Heiken H.

Expert Rev Anti Infect Ther. 2008 Jun;6(3):273-5. doi: 10.1586/14787210.6.3.273. No abstract available.

PMID:
18588490
20.

Impact of current antiretroviral therapies on neuroAIDS.

Vivithanaporn P, Gill MJ, Power C.

Expert Rev Anti Infect Ther. 2011 Apr;9(4):371-4. doi: 10.1586/eri.10.179. No abstract available.

PMID:
21504390

Supplemental Content

Support Center